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This study aims at developing a simulation system that predicts the optimal study design for attaining tracer steady-state conditions
in brain and blood rapidly. Tracer kinetics was determined from bolus studies and used to construct the system. Subsequently,
the system was used to design inputs for bolus infusion (BI) or programmed infusion (PI) experiments. Steady-state quantitative
measurements can be made with one short scan and venous blood samples. The GABAA receptor ligand [
11C]Flumazenil (FMZ)
was chosen for this purpose, as it lacks a suitable reference region.Methods. Five bolus [11C]FMZ-PET scans were conducted, based
on which population-based PI and BI schemes were designed and tested in five additional healthy subjects. The design of a PI was
assisted by an offline feedback controller. Results. The system could reproduce the measurements in blood and brain. With PI,
[11C]FMZ steady state was attained within 40min, which was 8min earlier than the optimal BI (B/I ratio = 55min). Conclusions.
The system can design both BI and PI schemes to attain steady state rapidly. For example, subjects can be [11C]FMZ-PET scanned
after 40min of tracer infusion for 40min with venous sampling and a straight-forward quantification. This simulation toolbox is
available for other PET-tracers.
1. Introduction
Among the kinetic modeling approaches to accurately quan-
tify the neuroreceptor availability, tissue compartment mod-
eling using arterial plasma as input is regarded as “gold
standard.”However, the requirement of an arterial line is both
invasive and less feasible in many clinical settings. Reference
tissue modeling approaches use a brain region devoid of
target neuroreceptors to obviate the arterial input function
[1]. However, for numerous tracers a suitable anatomical
reference region does not exist [2, 3]. As an alternative,
the tracer can be given as a constant infusion and when
steady-state conditions are attained, the patient can be posi-
tioned in the scanner [4]. At tracer steady state, venous
instead of arterial blood may be used as a representation of
the input function, since no arteriovenous difference exists
when there is no net tissue uptake [4, 5]. However, the time
to attain tracer steady state in brain and blood depends on
the kinetics of the individual tracer and may in theory vary
considerably from subject to subject.Thus, a preexperimental
simulation system aiming at testing new tracers and guiding
experimental procedures is important.
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Here we describe a simulation system to model tracer
uptake in plasma and brain regions based on the kinetics
of tracers using the tracer administration as input; thus, it
allows us to design the infusion scheme to attain fast steady-
state condition. We illustrate the methodology and test our
designed system using [11C]FMZ as an example. [11C]FMZ
is a non-subtype-selective antagonist of the central benzo-
diazepine (BZR) site of the 𝛾–aminobutyric acid (GABAA)
receptor [6]. As a reference region, pons and white matter
(WM) have been investigated, but both of them are suscep-
tible to noise which may explain the failure of simplified
reference tissue model (SRTM) to detect ipsilateral decreases
in hippocampal nondisplaceable binding potential BPND in
3/15 patients with hippocampal sclerosis [7]. Different data-
drivenmethodswith andwithout arterial input function have
been investigated for evaluating the feasibility of removing
the invasive arterial line and shortening the scan time from
90min to 60min in [8]. Even though it was concluded that
with 60min of scan time the multilinear reference tissue
model with fixed 𝑘
2
’ (MRTM2) could provide useful estima-
tion of regional BZR density, it gave an underestimation of
BPND due to the fact that a contribution from blood volume
was not taken into account. Image-derived input function has
also been applied to quantify [11C]FMZbinding [9]; however,
a number of arterial blood samples were still necessary.
Thus, a steady-state approach for conducting quantitative
[11C]FMZ-PET studies feasible in a clinical setting will be
useful. This approach provides estimations of distribution
volumes and is independent of assumptions for RTMs; thus,
it is a better choice when no appropriate reference region is
available. Even with an appropriate reference region at steady
state, the binding potential can be estimated by simply taking
the ratio 𝐶
𝑇
/𝐶ND − 1, which is free of model assumptions.
2. Materials and Methods
2.1. Simulation Framework. The simulation system is based
upon classical convolution analysis of systems in series. The
design is based on the metabolite-corrected plasma input
being convoluted with the impulse response function of the
brain tissue to obtain brain time-activity curve (TAC) and
is extended to model the plasma concentration by convolut-
ing the tracer injection scheme with the impulse response
function of the systemic circulation. The parameters in the
simulation framework are estimated from the experimental
data of dynamic scans and the system is assumed to be
stationary and linear.
The simulation framework is divided into three parts.
Part A depicts the computation of the metabolite-
corrected plasma concentration (𝐶
𝑃
) from the tracer admin-
istration scheme (𝐹Tracer):
ℎ (𝑡) =
𝑛
∑
𝑖=1
𝑎
𝑖
exp (−𝑏
𝑖
𝑡) ,
𝐶
𝑃
(𝑡) = 𝐹Tracer (𝑡) ⊗ ℎ (𝑡) ,
(1)
where ℎ(𝑡) is the impulse response of the systemic circulation.
A sum of three exponentials function was used for [11C]FMZ
and 𝑎
𝑖
and 𝑏
𝑖
are the rate constants with unit min−1; ⊗ is
the symbol of convolution. In the bolus experiments, the
input was administrated as a constant infusion over 20 s; thus,
𝐹Tracer(𝑡) is considered a step function with a duration of 20 s.
Part B depicts the computation of the total concentration
(parent compound and radio-labeled metabolites) in whole-
blood (𝐶
𝑊
) from 𝐶
𝑃
:
𝐹Parent (𝑡) = 𝑐1 exp (−𝑑1𝑡) + 𝑐2 exp (−𝑑2𝑡) + 𝑐3,
𝐹
𝑃2𝑊
(𝑡) = 𝑓
1
− 𝑓
2
exp (−𝑒
1
𝑡) ,
𝐶
𝑊
(𝑡) =
[𝐶
𝑃
(𝑡) /𝐹Parent (𝑡)]
𝐹
𝑃2𝑊
(𝑡)
.
(2)
As shown, part B contains two functions: the parent fraction
𝐹Parent(𝑡) and the plasma to whole-blood ratio 𝐹𝑃2𝑊(𝑡). 𝐶𝑃 is
first converted to the total tracer concentration in plasma by
the division by 𝐹Parent(𝑡), and then the tracer concentration
is further converted to 𝐶
𝑊
by the division by the plasma
to whole-blood ratio 𝐹
𝑃2𝑊
(𝑡). The form of these functions
depends on the chemical and biological properties of the radi-
oligand. For [11C]FMZ, exponential functions were chosen,
and 𝑐
𝑖
, 𝑑
𝑖
, 𝑒
𝑖
, and 𝑓
𝑖
are the parameters of the functions.
Part C is a tissue compartment model using 𝐶
𝑊
and 𝐶
𝑃
as inputs. The kinetics of [11C]FMZ can be described as a
one-tissue compartment (1TC) model [10, 11]. However, the
simulation system is designed for a two-tissue compartment
model; thus, 𝑘
3
and 𝑘
4
were set to zero in this case:
𝑑𝐶
1
(𝑡)
𝑑𝑡
= 𝐾
1
𝐶
𝑃
(𝑡) − 𝑘
2
𝐶
1
(𝑡) ,
𝐶PET (𝑡) = (1 − 𝑉𝐵) 𝐶1 (𝑡) + 𝑉𝐵𝐶𝑊 (𝑡) ,
(3)
where 𝐾
1
is the delivery rate constant from plasma to brain
tissue (𝐶
1
); 𝑘
2
is the washout rate constant from brain
tissue;𝐶PET describes the concentrationmeasured by the PET
scanner, that is, radioactivity from both tissue and blood; 𝑉
𝐵
is the blood volume in brain tissue, which is fixed to 5%.
2.2. Programmed Infusion: A Feedback Control System. By
using a proportional-controller (P-controller), an optimized
PI scheme can be obtained. An offline linear feedback control
system was developed, which designs the infusion protocol
prior to PET experiments. The P-controller adjusts the input
to the system proportionally to the difference between the
target signal (𝐶
𝑆
(𝑡)), which is the time-activity curve for a
preselected region in a steady-state study, and the system
output (𝐶PET(𝑡)), which is the simulated PET signal for the
same region; see Figure 1. It can be described by
𝑒 (𝑡) = 𝐶
𝑆
(𝑡) − 𝐶PET (𝑡) ,
𝐹Tracer (𝑡) = 𝐾𝑝𝑒 (𝑡) ,
(4)
where 𝐾
𝑝
is the proportional gain and it is set to 2.5 (deter-
mined by Simulink Control Design toolbox, Mathworks
Inc.); 𝑒(𝑡) is the instantaneous difference between the target
signal 𝐶
𝑆
(𝑡) and the system output 𝐶PET(𝑡). By providing
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Figure 1: A feedback system with a proportional-controller. The P-
controller adjusts the input to the system based on the difference
between the target signal 𝐶
𝑆
(𝑡) and outcome of the system.
a target signal, for example, the TAC of a receptor rich region
attaining steady state, the feedback system adjusts the input
𝐹Tracer(⋅) repeatedly at a fix time interval, which is set to 30 s,
to bring the system output similar to the target signal.
To design PI for [11C]FMZ, occipital cortex was chosen
as the target region, as it is a BZR rich region and requires
longer time to attain steady state in a BI setting. The target
was created based on the kinetics of this region, and the TAC
was maintained constant after reaching the peak induced by
a bolus administration. We used the coupled optimization
strategy, meaning the designed infusion scheme was also
applied to other regions to ensure that the optimization does
not cause a huge overshoot on the intermediate and low
binding regions, which delays the attainment of steady state.
In a classical feedback system, control signal can be negative,
but as this is not the case for the infusion flow rate, it is fixed
to zero instead.
2.3. Population-Based Infusion Scheme. The population-
based system representation is built upon a number of
bolus experiments to capture the tracer kinetics. To compare
the results from different studies both the plasma TACs
(Bq/mL) and the tissue TACs (Bq/mL) are normalized by
injected dose per bodyweight unit (kBq/kg), resulting in
standardized uptake values (SUVs) (g/mL). The three parts
of the simulation framework were fitted to the individual
bolus data. Mean values of the subject-specific parameters
across all bolus experiments were used for population-based
simulations.
2.4. Human Studies. Sixteen PET scans were conducted in
ten healthy subjects (3 men; mean age ± SD: 26 ± 8 years,
range 20–46 years). The study was approved by the Regional
Ethics Committee (KF 01280377) and informed consent was
obtained from all subjects. All subjects had no history of
neurological or psychiatric disorders. Physical examinations,
ECG, and routine blood test were normal in all subjects.
The protocols carried out for each subject are listed in
Table 1. Five bolus dynamic PET scans were conducted to
adapt the kinetics of [11C]FMZ to the simulation system. To
verify that the simulation system can represent the dynamic
and physiological characteristics of [11C]FMZ, one of the
subjects was studied twice. First, a bolus alone experiment
was done and based upon the kinetic parameters determined
from this bolus study the optimal PI scheme was determined
for this subject. Next, a PI experiment was conducted in
the same subject. Finally, based on the population-based
Table 1: List of subjects and protocols involved in this study.
Bolus Bolus infusion Programmed infusion
Subj 1 X
Subj 2 X
Subj 3 X
Subj 4 X
Subj 5 X Subject-specific
Subj 6 B/I = 55min Population-based
Subj 7 B/I = 55min Population-based
Subj 8 B/I = 55min Population-based
Subj 9 B/I = 55min Population-based
Subj 10 B/I = 55min Population-based
Note: B/I is the bolus infusion ratio.
simulation, five pairs of PI and BI experiments were done in
five new subjects.
2.5. Radiochemistry and PET Image Acquisition. Flumaze-
nil was labeled with carbon-11 using methyl triflate [12],
which was prepared online from [11C]methyl iodide [13].
Radiochemical purity of [11C]FMZ was greater than 99%.
At the time of injection, the specific radioactivity was
279.7GBq/𝜇mol (range, 23.3–711 GBq/𝜇mol; 𝑛 = 16); the
injected radioactivity was 340.7MBq (range, 46.4–699MBq;
𝑛 = 16); and the total radioactivity of the double-scanned
subjects received was 379.0MBq (range, 118.7–733MBq; 𝑛 =
6). The average injected mass was 1.34 𝜇g (range, 0.03–
8.48 𝜇g; 𝑛 = 16). The BI and PI experiments were performed
using a computer controlled infusion pump (Harvard PHD
2000 Infusion pump).
The high-resolution research tomography (HRRT) scan-
ner (Siemens AG), running in list-mode, was used for acqui-
sition of PET data. Emission scans started simultaneously
with the injection/infusion of tracer. Data were recorded in
3-dimensionalmode for 90min for bolus studies and 120min
for BI and PI studies. For the dynamic scans, PET data were
reconstructed into 35 dynamic frames of increasing length
(6 × 5, 10 × 15, 4 × 30, 5 × 120, 5 × 300, and 5 × 600 s) using the
Ordered Subset Expectation Maximization iterative method;
and for the longer scans 3 × 600 s frames were added. Images
consist of 207 planes of 256 × 256 voxels with the size of 1.22 ×
1.22 × 1.22mm.
Structural brain imaging (T1- and T2-weighted) of mag-
netic resonance imaging (MRI) was performed with a 3.0 T
Trio scanner (Siemens Medical Solutions, Erlangen, Ger-
many) with a voxel size of 1 × 1 × 1mm.
2.6. Input Measurement. In the infusion experiments, can-
nulas were inserted into both cubital veins for radiotracer
administration and blood sampling, respectively. In the bolus
studies, a cannula was inserted into the radial artery of
the nondominant arm for arterial blood sampling. During
the first 10min of scanning, the coincidences were counted
continuously in the whole-blood with an ABSS autosampler
(Allogg Technology) and three samples were drawnmanually
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Table 2: Metabolite-corrected plasma time-activity curve fitting.
a
1
(min−1) b
1
(min−1) a
1
/b
1
a
2
(min−1) b
2
(min−1) a
2
/b
2
a
3
(min−1) b
3
(min−1) a
3
/b
3
Bolus-1 2.503 2.579 0.97 0.109 0.107 1.02 0.045 0.010 4.56
Bolus-2 0.394 0.765 0.52 5.125 6.302 0.81 0.079 0.022 3.61
Bolus-3 0.455 0.860 0.53 6.353 7.990 0.80 0.103 0.029 3.58
Bolus-4 4.233 5.103 0.83 0.157 0.134 1.17 0.065 0.017 3.89
Bolus-5 6.544 7.142 0.92 0.189 0.178 1.06 0.086 0.018 4.79
Mean ± SD 0.75 ± 0.22 0.97 ± 0.16 4.09 ± 0.56
Note: 𝑎𝑖 and 𝑏𝑖 are the rate constants of the impulse response function to represent the concentration of parent radioligand in arterial plasma; see (1).
to rectify the autosamples. To determine the plasma towhole-
blood ratio, blood samples were drawn manually at 18 time
points with increasing time intervals. They were measured in
a well counter (Cobra 5003; Packard Instruments) and data
were decay-corrected to the time of injection. In addition,
nine blood samples were drawn during scanning for metabo-
lite analysis by radio-high performance liquid chromatog-
raphy (HPLC). All the equipment was cross-calibrated to
the HRRT scanner. The percentage of parent compound was
fitted using 𝐹Parent(𝑡). The metabolite-corrected plasma input
function was calculated as the product of this biexponential
function and the total plasma concentration.
2.7. Data Analysis. PET images were inspected for move-
ments, using a set of in-house MATLAB based functions and
an AIR 5.2.5 algorithm [14]: each dynamic frame was filtered
by a Gaussian 3D filter (FWHM 10mm) and thresholded to
only include brain voxels.Thereafter, the rigid transformation
was estimated for the frames with length greater than 15 s to
the first 5min frame, which has less noise than other frames.
For all images, the detected median voxel movement was less
than the precision of the algorithm that is 3mm. Thus, no
movement correction was needed.
Applying the coregistration algorithm implemented in
Statistical Parametric Mapping (SPM) [15], the MRI image
was coregistered to the mean PET image of the same subject
from time 75 s to 20min after the start of scanning, as
within this time interval tracer distribution better reflects
the cerebral perfusion. An automatic delineation of VOIs
was performed using probability maps [16]. The TACs of
nine VOIs were then calculated. Radioactivity in regions
located in both hemispheres was calculated as the weighted
average of radioactive concentrations in left and right sides
weighted with the VOI volume. Finally, each tissue TAC was
normalized by the injected dose per bodyweight unit of the
subject, yielding a regional SUV.
Bolus data were fitted to a 1TC model. The Akaike
Information Criterion (AIC) was used to determine the
number of exponentials in modeling arterial plasma curve
(𝐶
𝑃
) that is part A of the simulation system. In general,
we consider that brain tissue attains steady-state condition
when the individual measurements in the time-activity curve
are within 5% of the plateau. Due to the noise in the data,
the plateau was determined by averaging the five last time-
activity values in order to get a robust estimate. To investigate
if both blood and brain tissues attained steady state, the time
development of distribution volume 𝑉
𝑇
was studied for
measuring the time of attaining steady-state conditions. The
distribution volume was calculated as 𝑉
𝑇
= 𝐶
𝑇
/𝐶
𝑃
= (𝐶PET −
𝑉
𝐵
𝐶
𝑊
)/(1 −𝑉
𝐵
)/𝐶
𝑃
. The coefficient of variance (COV) of the
mean 𝑉
𝑇
was used to measure the robustness of BI and PI
across five infusion subjects. COV is the standard deviation
of the measurements across subjects divided by the mean.
PMOD software (version 3.0; PMOD Technologies Inc.)
was used for kinetic modeling. Data preprocessing and
function fitting were done in MATLAB, so was the statistical
analysis: paired-sample 𝑡-test and Pearson’s linear correla-
tion; and the simulation system was designed in Simulink
(Simulink version 7.5; MATLAB version 7.10; Mathworks
Inc.).
3. Results
3.1. Bolus Studies. The TACs of metabolite-corrected plasma
from the 5 bolus studies were fitted to part A (1) separately.
The lowest AIC values suggested a sum of three exponentials.
The microparameters are given in Table 2. The variations of
the microparameters over 5 studies were pronounced, which
may be due to modeling uncertainty of the microparameters
and interindividual variability. However, the macroparam-
eters 𝑎
𝑖
/𝑏
𝑖
were much more stable and comparable across
subjects. The results of kinetic modeling are presented in
Table 3.
3.2. Bolus Infusion Studies. For population-based bolus infu-
sion studies, the system was built based on averaged kinetic
parameters from the bolus studies. A B/I ratio of 55min
generated the fastest steady-state conditions across receptor
rich, medium, and poor regions in the simulation.
Five PET studies with a B/I ratio of 55min were then
conducted in five new subjects. Figure 2 shows the mean
SUVs and the standard deviation for nine regions. The B/I
protocol of 55min did bring the brain tissues to steady-
state condition, at which point the venous tracer concentra-
tion equals the arterial concentration. For the first 80min,
the HPLC measurements were quite reliable, but for the
later samples the variation of the metabolite measurement
increased as a function of lower counts.Thus, the distribution
volume as a function of time 𝑉
𝑇
(𝑡) was only calculated from
the beginning of tracer infusion to 80min. The plateau for
steady-state estimation was calculated as an average of 𝑉
𝑇
(𝑡)
from time of 35min (frame 30) to 80min (frame 34) after
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Table 3: Model parameters of one-tissue compartment model (1TC) and steady-state approaches: programmed infusion (PI) and bolus
infusion (BI).
1TC PI BI
𝐾
1
(mLmin−1mL−1) 𝑘
2
(min−1) 𝑉
𝑇
𝑉
𝑇
𝑉
𝑇
Occipital cortex 0.43 ± 0.07 0.05 ± 0.01 8.05 ± 0.56 9.00 ± 1.56 8.89 ± 1.73
Neocortex 0.41 ± 0.06 0.06 ± 0.01 7.36 ± 0.46 8.16 ± 1.30 7.97 ± 1.60
Hippocampus 0.28 ± 0.04 0.05 ± 0.01 6.11 ± 0.49 6.79 ± 1.44 6.57 ± 1.42
Cerebellum 0.41 ± 0.06 0.08 ± 0.01 4.97 ± 0.70 5.62 ± 0.85 5.39 ± 1.12
Thalamus 0.44 ± 0.06 0.11 ± 0.01 4.13 ± 0.38 4.83 ± 1.11 4.66 ± 0.93
Pallidostriatum 0.45 ± 0.07 0.13 ± 0.02 3.35 ± 0.34 3.86 ± 0.93 3.83 ± 0.75
Midbrain 0.25 ± 0.04 0.16 ± 0.01 1.59 ± 0.17 2.05 ± 0.31 1.92 ± 0.28
White matter 0.11 ± 0.02 0.12 ± 0.01 0.93 ± 0.08 1.12 ± 0.13 1.11 ± 0.20
Pons 0.31 ± 0.06 0.33 ± 0.04 0.91 ± 0.09 1.10 ± 0.15 0.85 ± 0.07
The mean and standard deviation are reported. 𝑉𝑇 is defined as 𝐾1/𝑘2 for 1TC and 𝐶𝑇/𝐶𝑃 for PI and BI averaging from 35 to 80min after the beginning of
tracer administration.
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Figure 2: Bolus infusion studies with a bolus infusion ratio B/I =
55min (𝑛 = 5): mean and standard deviation (one direction) of the
standard uptake volume in occipital cortex, neocortex, hippocam-
pus, cerebellum, thalamus, pallidostriatum, midbrain, white matter,
and pons.
tracer administration. During one BI scan the HPLC analysis
failed and thus Table 4 gives the averaged time of steady-
state attainment across 4 BI studies. The mean and standard
deviation of the averaged 𝑉
𝑇
from 35 to 80min across 4
subjects are given in Table 3.
3.3. Programmed Infusion Studies. A subject-specific PI study
was carried out in one subject to verify the simulation
system. This subject-specific PI scheme was determined by
the simulation system using the kinetic parameters from
the bolus study of the same subject. The subject-specific PI
scheme designed through a P-controller feedback system is
given in Figure 3(c).Most prominently the pumpwas stopped
for 14min after the initial 6min of infusion and thereafter
a slow infusion took place with flow rates updated every
Table 4: Time for the distribution volume attaining steady-state
conditions for population-based programmed infusion (PI) and
bolus infusion (BI).
Time (min)
PI BI
Occipital cortex 25 ± 12 38 ± 14
Neocortex 20 ± 9 35 ± 11
Hippocampus 34 ± 10 29 ± 9
Cerebellum 27 ± 14 39 ± 10
Thalamus 30 ± 14 42 ± 9
Pallidostriatum 40 ± 14 41 ± 0
Midbrain 27 ± 14 36 ± 6
White matter 45 ± 12 53 ± 9
Pons 44 ± 15 53 ± 9
The mean and standard deviation are reported. The steady state was
determined as the time point, when the change of the time-activity curve was
within ±5% of the plateau.
30 s. The simulation system could reproduce the SUVs for
themetabolite-corrected plasma and the brain tissue (Figures
3(a) and 3(b)), and the designed PI scheme brought the brain
tissue into steady state (Figure 3(c)).
The population-based PI scheme was designed using the
averaged kinetic parameters across five bolus studies. The
scheme suggested an initial infusion of 4min and a pause of
17min before restarting infusion. SUVs of 9 brain regions are
shown in Figure 4. Table 4 gives the averaged time of steady-
state attainment across 5 PI scans measured by the time
development of𝑉
𝑇
. The experimental results showed that the
PI scheme brought the blood and brain tissues to steady-state
condition earlier than the BI scheme (𝑝 = 0.0048); across
the brain regions, the time shortened by the PI scheme was
8min on average.TheCOVof themean𝑉
𝑇
from 35 to 80min
of each scan in different brain regions was calculated. No
significant difference between BI and PI of the estimated 𝑉
𝑇
was found (𝑝 = 0.712). The mean and standard deviation
of 𝑉
𝑇
averaged from 35 to 80min after the beginning of the
PI studies (𝑛 = 5) are given in Table 3. The mean 𝑉
𝑇
values
across four BI studies correlated significantly with the mean
6 BioMed Research International
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Figure 3: The standardized uptake values (SUVs) of a bolus and a programmed infusion (PI) study on the same subject. (a) and (b) show
arterial plasma SUV and occipital cortex SUV of a bolus study, respectively. From the bolus data, a PI scheme was designed. (c) shows the
infusion scheme; themeasured occipital cortex SUV; the simulated occipital cortex SUV “simu output” with 𝑘
2
= 0.06min−1, model parameter
from the bolus study; the estimated SUV “simu true” with 𝑘
2
= 0.096min−1, suggested by the measured PI data; and the definition of steady
state “ss”, which is ±5% of the plateau. The infusion scheme is unitless, and it shows the relative development of infusion with time.
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Figure 4: Programmed infusion: mean and standard deviation
(one direction) of the standard uptake volume in occipital cortex,
neocortex, hippocampus, cerebellum, thalamus, pallidostriatum,
midbrain, white matter, and pons (𝑛 = 5).
𝑉
𝑇
values across five PI studies (𝑟 = 0.9996, 𝑝 = 4.03𝑒 − 12).
Furthermore, they also correlated with the mean 𝑉
𝑇
values
from 1TC modeling of 5 bolus studies: 𝑟 = 0.9991, 𝑝 =
6.52𝑒 − 11 (BI versus 1TC); and 𝑟 = 0.9996, 𝑝 = 3.70𝑒 − 12
(PI versus 1TC).The infusion studies overestimated the𝑉
𝑇
by
10.5% (BI) and 16.5% (PI) compared to 1TC.
4. Discussion
The purpose of this study was to introduce a simulation
system that utilizes the known tracer kinetics from bolus
studies to apply it to the design of PI and BI experiments in
humans. The concept of our simulation system is similar to
theUIPump-systemwhichwas tested in Sprague-Dawley rats
for microPET scanning [17]. The UIPump-system is feasible
to small animal studies, where the tracer kinetics is faster than
in humans. However, for human PET amore complex system
is necessary. In contrast to the UIPump-system approach
which simulates how the rodent body handles an exposure of
a radioligandwith one impulse response function, we divided
the process into three parts: part A simulates the metabolite-
corrected plasma concentration using the infusion paradigm;
part B prepares the total tracer concentration in whole-blood
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using the output frompart A; then, part C simulates the tissue
TACs using blood TACs as inputs. The simulation output
from each part was verified with experimental data.
With the proposed simulation system, an infusion
scheme can be designed to replace arterial blood sampling
by a number of venous samples for quantitative estimation of
tracer binding. Although taking only a single blood sample
has been proposed [18], we recommend taking several venous
blood samples. Firstly, it is to ascertain the steady-state
attainment and, secondly, to increase the precision of the
measure without increasing the invasiveness, given that a
venous line is already in place.
4.1. The Simulation System. The occipital cortex is the VOI
with the highest [11C]FMZbinding (Table 3) and accordingly,
following a constant infusion of [11C]FMZ, steady state will
be attained later in this VOI compared to other VOIs with
a lower binding. Thus, we chose the occipital cortex as
the target region to design a PI scheme with the feedback
controller. By optimizing the infusion scheme for the VOI
with the highest binding potential, the TACs of the low
binding VOIs will initially overshoot, as illustrated by the
experimental results (Figure 4). The P-controlled feedback
system suggested a negative input after the initial infusion to
attain the fastest steady-state conditions.Thus, a nonnegative
constraint was applied when designing the infusion scheme,
which subsequently introduced a pause during the course
of infusion. The drop in the high binding regions (i.e., 10–
25min) was mainly due to the pause.
To validate the simulation system, subject 5 was studied
twice: first, a bolus study was done, based upon which the
optimal PI scheme was determined; then, a PI experiment
was conducted. The infusion scheme and the experimental
and simulated SUVs are shown in Figure 3. The comparison
of the simulated and the experimental data implies that the
simulation system could represent the outcomes from the
[11C]FMZ experiments. The difference between the simu-
lated output and the measured SUV is probably related to
the uncertainty in the estimation of the compartment model
parameters from the bolus experiment and interexperiment
variation from the bolus to the PI experiment. Based on
the behavior of the simulated SUV, the 𝑘
2
= 0.060min−1
estimated from the bolus data was too low compared to
the actual 𝑘
2
of the subject in the PI experiment. When
increasing the 𝑘
2
to 0.096min−1 and keeping 𝐾
1
unchanged,
the resulting estimation aligned with the measured SUV
much better.
4.2. The PET Experiments. The averaged 𝑉
𝑇
curve across five
PI experiments attained steady state within 40min for high
and intermediate binding regions. Identification of steady-
state condition was challenging, particularly in receptor
poor regions, where the binding is more sensitive to noise,
especially at the latter frames when count statistics is low.
There is no good way to reduce noise in TACs except to
inject a higher radioactivity dose or to confine binding
assessment to larger brain regions only. The same applies
to the plasma measurements, where the low count statistics
reduces the accuracy of the measurements, especially in the
HPLC measurements.
A limitation of BI studies and PI studies is that they
require use of population-based infusion schemes. The
interindividual variability in terminal plasma clearance is
clearly demonstrated inTable 2 and different subjects attained
tracer steady state at slightly different times in different VOIs
(Table 4). Individual variation in time to attain tracer steady
state using a population-based infusion scheme is reduced by
waiting for data acquisition (PET scan and blood sampling)
until the majority of subjects are expected to have attained
steady state in blood and brain and by dividing the acquisition
time into 5–10min frames for post hoc verification of tracer
steady state and possible exclusion of frames. Compared to
the population-based BI scheme, the PI scheme hastened the
steady-state attainment by 8min on average, when looking at
the time development of the distribution volume. Whereas
this difference may not sound all that impressive, for carbon-
11 labeled tracers, it still means gaining 24% of radioactivity.
In addition, the difference may be larger for other radioli-
gands. Compared to BI scheme which is determined by only
one parameter, the B/I ratio, PI enables more sophisticated
input patterns based on both the tracer kinetics in plasma and
brain tissues, which leads to a faster steady-state condition
attainment.
5. Conclusion
We here, by example of [11C]FMZ, introduce a simulation
system that reproduces both the blood and brain time-
activity curves from PET experiments. Thus, the system can
be used to design infusion schemes, both BI and PI, to bring
both the blood and brain into steady state as early as possible.
As expected, the PI scheme attained steady-state conditions
faster than the optimal BI scheme. We recommend starting
[11C]FMZ-PET scanning at 40min after the beginning of
tracer administration and scan for 40min with, for example,
5 venous samples and a straight-forward computation of the
distribution volume.
Abbreviations
BI: Bolus infusion
PI: Programmed infusion
FMZ: Flumazenil
SRTM: Simplified reference tissue model
TAC: time-activity curves
1TC: One-tissue compartment model
P-controller: Proportional-controller
SUV: Standardized uptake value
HRRT: High-resolution research tomography
COV: Coefficient of variance
VOI: Volume of interest.
Competing Interests
The authors declare that they have no competing interests
regarding the publication of this paper.
8 BioMed Research International
Acknowledgments
This study was supported by the European Union’s Sev-
enth Framework Programme (FP7/2007–2013) under Grant
Agreement no. HEALTH-F2-2011-278850 (INMiND), Øst-
dansk Sundhedsvidenskabeligt Forskningsforum, the Danish
Council for Independent Research, the EU 7th Framework
Programme Euripides (Grant Agreement no. 201380), Novo
Nordisk Foundation, and the Lundbeck Foundation (Cimbi).
The authors gratefully acknowledge the John and Birthe
Meyer Foundation for the donation of the Cyclotron and PET
scanner and Toyota-Fonden, Denmark, for the donation of
the HPLC. Nic Gillings, Bente Dall, and HaroonMalik Arfan
are acknowledged for their expert assistance. The authors
are also grateful to Department of Nuclear Medicine and
PET Research, VU University Medical Centre, Amsterdam,
Netherlands, for sharing their knowledge and experience on
[11C]FMZ.
References
[1] A. A. Lammertsma and S. P. Hume, “Simplified reference tissue
model for PET receptor studies,” NeuroImage, vol. 4, no. 3, pp.
153–158, 1996.
[2] L. H. Pinborg, C. Videbaek, M. Ziebell et al., “[123I]epidepride
binding to cerebellar dopamineD
2
/D
3
receptors is displaceable:
implications for the use of cerebellum as a reference region,”
NeuroImage, vol. 34, no. 4, pp. 1450–1453, 2007.
[3] L. Feng, C. Svarer, G. Thomsen et al., “In vivo quantification
of cerebral translocator protein binding in humans using
6-chloro-2-(4󸀠-123I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-
a]pyridine-3-acetamide SPECT,” Journal of Nuclear Medicine,
vol. 55, no. 12, pp. 1966–1972, 2014.
[4] N. A. Lassen, “Neuroreceptor quantitation in vivo by the
steady-state principle using constant infusion or bolus injection
of radioactive tracers,” Journal of Cerebral Blood Flow and
Metabolism, vol. 12, no. 5, pp. 709–716, 1992.
[5] R. E. Carson, M. A. Charming, R. G. Blasberg et al., “Compar-
ison of bolus and infusion methods for receptor quantitation:
application to [18F]cyclofoxy and positron emission tomogra-
phy,” Journal of Cerebral Blood Flow andMetabolism, vol. 13, no.
1, pp. 24–42, 1993.
[6] M. Maziere, P. Hantraye, C. Prenant, J. Sastre, and D. Comar,
“Synthesis of ethyl 8-fluoro-5,6-dihydro5- [11C]methyl-6-oxo-
4H-imidazo[1,5-a] [1,4]benzodiazepine-3-carboxylate (RO
15.1788-11C): a specific radioligand for the in vivo study of
central benzodiazepine receptors by positron emission tomo-
graphy,” The International Journal of Applied Radiation and
Isotopes, vol. 35, no. 10, pp. 973–976, 1984.
[7] A. Hammers, P. Panagoda, R. A. Heckemann et al.,
“[11C]Flumazenil PET in temporal lobe epilepsy: do we need
an arterial input function or kinetic modeling?” Journal of
Cerebral Blood Flow and Metabolism, vol. 28, no. 1, pp. 207–216,
2008.
[8] I. Miederer, S. I. Ziegler, C. Liedtke et al., “Kinetic modelling of
[11C]flumazenil using data-driven methods,” European Journal
of Nuclear Medicine and Molecular Imaging, vol. 36, no. 4, pp.
659–670, 2009.
[9] S. M. Sanabria-Boho´rquez, A. Maes, P. Dupont et al., “Image-
derived input function for [11C]flumazenil kinetic analysis in
human brain,” Molecular Imaging and Biology, vol. 5, no. 2, pp.
72–78, 2003.
[10] U. M. H. Klumpers, D. J. Veltman, R. Boellaard et al., “Compar-
ison of plasma input and reference tissue models for analysing
[11C]flumazenil studies,” Journal of Cerebral Blood Flow and
Metabolism, vol. 28, no. 3, pp. 579–587, 2008.
[11] R. A. Koeppe, V. A. Holthoff, K. A. Frey, M. R. Kilbourn,
and D. E. Kuhl, “Compartmental analysis of [11C]flumazenil
kinetics for the estimation of ligand transport rate and receptor
distribution using positron emission tomography,” Journal of
Cerebral Blood Flow and Metabolism, vol. 11, no. 5, pp. 735–744,
1991.
[12] K. Na˚gren and C. Halldin, “Methylation of amide and
thiol functions with [11C]methyl triflate, as exemplified by
[11C]NMSP, [11C]flumazenil and [11C]methionine,” Journal of
Labelled Compounds and Radiopharmaceuticals, vol. 41, no. 9,
pp. 831–841, 1998.
[13] D. M. Jewett, “A simple synthesis of [11C]methyl triflate,” Inter-
national Journal of Radiation Applications and Instrumentation
A, vol. 43, no. 11, pp. 1383–1385, 1992.
[14] R. P.Woods, S. R. Cherry, and J. C.Mazziotta, “Rapid automated
algorithm for aligning and reslicing pet images,” Journal of
Computer Assisted Tomography, vol. 16, no. 4, pp. 620–633, 1992.
[15] J. Ashburner and K. Friston, “Multimodal image coregistration
and partitioning—a unified framework,”NeuroImage, vol. 6, no.
3, pp. 209–217, 1997.
[16] C. Svarer, K. Madsen, S. G. Hasselbalch et al., “MR-based
automatic delineation of volumes of interest in human brain
PET images using probability maps,” NeuroImage, vol. 24, no.
4, pp. 969–979, 2005.
[17] O. Eriksson, A. Wallberg, S. Syva¨nen, R. Josephsson, B.
Lngstro¨m, and M. Bergstro¨m, “A computerized infusion pump
for control of tissue tracer concentration during positron emis-
sion tomography in vivo pharmacokinetic/pharmacodynamic
measurements,” BMC Medical Physics, vol. 8, no. 1, article 2,
2008.
[18] Y. Kimura, F. G. Sime´on, S. S. Zoghbi et al., “Quantification of
metabotropic glutamate subtype 5 receptors in the brain by an
equilibrium method using 18F-SP203,” NeuroImage, vol. 59, no.
3, pp. 2124–2130, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
